title: Effect of FC43se on endotoxin-induced disseminated intravascular coagulation in rats.
abstract: Perfluorotributylamine/Pluronic F68 Stem-Emulsion (FC43se), which is a blood substitute, was assessed for its effectiveness on disseminated intravascular coagulation (DIC) in the rat model. Rats were infused intravenously with 2.5 mg/kg of Escherichia coli lipopolysaccharide (Escherichia coli 055:B5 lipopolysaccharide B) for four hours. At the same time, FC43se or normal physiological saline was infused at 2.5 ml/kg/hr. The white blood cell and platelet counts, prothrombin time (PT), activated partial thromboplastin time (APTT), and the plasma levels of interleukin-1 beta (IL-1 beta), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), and tumor necrosis factor alpha (TNF alpha) were determined at 4 hr. The infusion of FC43se markedly prevented a decrease in platelet counts (p = 0.0004) and a prolongation of both PT and APTT (p < 0.05 and p < 0.03 each). The serum level of IL-1 beta and IL-4 showed no significant change. The serum level of IL-6, IL-10 and TNF alpha increased significantly (p = 0.0007, p = 0.0004 and p < 0.05 each) with infusion of FC43se in rats treated with bacterial endotoxin. FC43se has beneficial effects on endotoxin-induced DIC as an anticoagulant and anti-inflammatory cytokine induced agent.
authors.affiliation: First Department of Surgery, School of Medicine, Hiroshima University Faculty of Medicine, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Ochikubo
authors.forename: S
authors.initials: S
authors.lastname: Wada
authors.forename: Y
authors.initials: Y
authors.lastname: Sugawara
authors.forename: T
authors.initials: T
authors.lastname: Sueda
authors.forename: Y
authors.initials: Y
authors.lastname: Matsuura
mesh_terms: D000818:Animals; D001802:Blood Substitutes / Q000494:pharmacology*; D016207:Cytokines / Q000378:metabolism*; D004211:Disseminated Intravascular Coagulation / Q000139:chemically induced / Q000503:physiopathology*; D004926:Escherichia coli; D005466:Fluorocarbons / Q000494:pharmacology*; D007375:Interleukin-1 / Q000378:metabolism; D016753:Interleukin-10 / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D007958:Leukocyte Count / Q000187:drug effects; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D010314:Partial Thromboplastin Time; D010976:Platelet Count / Q000187:drug effects; D020442:Poloxamer / Q000494:pharmacology*; D011517:Prothrombin Time; D051381:Rats; D017208:Rats, Wistar; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D001802:Blood Substitutes; D016207:Cytokines; D005466:Fluorocarbons; D007375:Interleukin-1; D015850:Interleukin-6; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D020442:Poloxamer; D016753:Interleukin-10; D015847:Interleukin-4; C008807:perfluorotributylamine